Krebs Biochemicals & Industries
Healthcare
KREBSBIO NSE
₹57.10 +1.18 (+2.11%)
- P/E
- Not meaningful: loss-making over the last twelve months
Close 4 Nov 2026 ₹57.10 −11.02 −16.2% 1Y
Start ₹68.12
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Standalone · TTM
- ROCE
- −15.40%
- Debt to Equity
- Not meaningful: shareholders’ equity is negative
- EPS (TTM)
- −₹6.54
- Book Value
- −₹79.14
- Market Cap
- —
- P/E (TTM)
- Not meaningful: loss-making over the last twelve months
- P/B
- Not meaningful: book value is negative
- ROE
- Not meaningful: shareholders’ equity is negative
- Dividend Yield
- 0.00%
- EBITDA
- −₹3.40 Cr
- 52W High
- ₹76.85
- 52W Low
- ₹38.33
- Day Range
- ₹54.50 – ₹57.50
- Volume
- 14,886
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Krebs Biochemicals & Industries (this company) | ₹57.10 | — | ₹120 Cr | — | 0.00% | — | −15.40% | ₹25 Cr | −₹14 Cr |
| Median 8 companies | ₹1,587.70 | 38.81 | ₹1,25,337 Cr | 4.77 | 0.44% | 16.50% | 16.65% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
31 Poor
Data confidence 86/100
surveillance:ASM1
Category scores
- Quality
- 27
- Poor
- Returns, margins, earnings quality 22% weight
- Valuation
- 30
- Poor
- Cheap vs sector & own history 24% weight
- Growth
- 9
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 15
- Poor
- Solvency, leverage, coverage 9% weight
- Momentum
- 51
- Average
- Trend strength, vol-adjusted 12% weight
- Ownership
- 50
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
No strengths listed
Weaknesses
2- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -15.1% over past five years.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bearish | 12 | 7 | 0 |
| Oscillators | Bearish | 2 | 7 | 0 |
| Moving Averages | Strong Bearish | 10 | 0 | 0 |
Oscillators
Bearish
Bearish
2
Neutral
7
Bullish
0
Overall
Strong Bearish
Bearish
12
Neutral
7
Bullish
0
Moving Averages
Strong Bearish
Bearish
10
Neutral
0
Bullish
0
Key readings
- RSI (14)
- 49.00
- Neutral
- MACD (12,26,9)
- −0.38
- Bearish
- SMA (50)
- 57.50
- Bearish
- SMA (200)
- 57.78
- Bearish
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | +37.41% |
|---|---|
| 5Y | −14.97% |
| 3Y | −22.72% |
| 1Y | −44.19% |
| TTM | −29.74% |
Net profit
| 10Y | Loss widened by ₹1 Cr |
|---|---|
| 5Y | Loss narrowed by ₹11 Cr |
| 3Y | Loss narrowed by ₹8 Cr |
| 1Y | Loss narrowed by ₹10 Cr |
| TTM | Loss narrowed by ₹13 Cr |
Operating cash flow
| 10Y | Outflow narrowed by ₹13 Cr |
|---|---|
| 5Y | Outflow narrowed by ₹13 Cr |
| 3Y | Outflow narrowed by ₹23 Cr |
| 1Y | Outflow narrowed by ₹6 Cr |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | Tiny sales |
|---|---|
| 5Y | +12.50 pp |
| 3Y | +9.94 pp |
| 1Y | +14.05 pp |
| TTM | +31.51 pp |
Revenue by year
| Mar 2017 | ₹3.00 Cr |
|---|---|
| Mar 2018 | ₹34.00 Cr |
| Mar 2019 | ₹48.00 Cr |
| Mar 2020 | ₹33.00 Cr |
| Mar 2021 | ₹54.00 Cr |
| Mar 2022 | ₹60.00 Cr |
| Mar 2023 | ₹52.00 Cr |
| Mar 2024 | ₹50.00 Cr |
| Mar 2025 | ₹43.00 Cr |
| Mar 2026 | ₹24.00 Cr |
Net profit by year
| Mar 2017 | −₹16.00 Cr |
|---|---|
| Mar 2018 | −₹18.00 Cr |
| Mar 2019 | −₹20.00 Cr |
| Mar 2020 | −₹29.00 Cr |
| Mar 2021 | −₹28.00 Cr |
| Mar 2022 | −₹45.00 Cr |
| Mar 2023 | −₹25.00 Cr |
| Mar 2024 | −₹20.00 Cr |
| Mar 2025 | −₹27.00 Cr |
| Mar 2026 | −₹17.00 Cr |
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 10.58 | 14.89 | 12.98 | 11.97 | 12.89 | 12.86 | 11.47 | 6.1 | 5.48 | 4.17 | 7.27 | 6.81 | 6.98 | 5.79 |
| Expenses | 13.2 | 15.79 | 15.07 | 15.09 | 15.08 | 15.58 | 16.18 | 11.51 | 7.57 | 6.97 | 6.97 | 7.67 | 6.16 | 7.72 |
| Operating Profit | −2.62 | −0.9 | −2.09 | −3.12 | −2.19 | −2.72 | −4.71 | −5.41 | −2.09 | −2.8 | 0.3 | −0.86 | 0.82 | −1.93 |
| OPM % | −24.76% | −6.04% | −16.1% | −26.07% | −16.99% | −21.15% | −41.06% | −88.69% | −38.14% | −67.15% | 4.13% | −12.63% | 11.75% | −33.33% |
| Other Income | 0.04 | 0.17 | 0.03 | 0.21 | 0.03 | 0.09 | 0.25 | 0.34 | 0.01 | 0.01 | 0 | 2 | 0.16 | 0.04 |
| Interest | 1.1 | 1.13 | 1.19 | 1.27 | 1.32 | 1.42 | 1.56 | 1.61 | 1.65 | 1.73 | 1.79 | 1.91 | 1.88 | 1.9 |
| Depreciation | 1.65 | 1.71 | 1.73 | 1.67 | 1.69 | 1.71 | 1.72 | 1.57 | 1.6 | 1.62 | 1.63 | 1.57 | 1.59 | 1.61 |
| PBT | −5.33 | −3.57 | −4.98 | −5.85 | −5.17 | −5.76 | −7.74 | −8.25 | −5.33 | −6.14 | −3.12 | −2.34 | −2.48 | −5.4 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0.24% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | −5.33 | −3.57 | −4.98 | −5.85 | −5.17 | −5.76 | −7.74 | −8.27 | −5.32 | −6.14 | −3.13 | −2.34 | −2.48 | −5.4 |
| EPS (₹) | −2.47 | −1.66 | −2.31 | −2.71 | −2.4 | −2.67 | −3.59 | −3.84 | −2.47 | −2.85 | −1.45 | −1.09 | −1.15 | — |
Sep 2026: from the results filed on 29 Oct 2026, ahead of the full statement, so some rows are blank.
Profit & Loss
₹ Cr| Particulars | Mar 2015 6m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 1 | 3 | 34 | 48 | 33 | 54 | 60 | 52 | 50 | 43 | 24 | 25 |
| Expenses | 5 | 14 | 11 | 41 | 58 | 52 | 71 | 94 | 68 | 59 | 58 | 29 | 28 |
| Operating Profit | −5 | −12 | −8 | −8 | −10 | −19 | −18 | −34 | −16 | −9 | −15 | −5 | −3 |
| OPM % | — | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | −248% | −22% | −20% | −56% | −33% | −57% | −30% | −17% | −35% | −23% | −10% |
| Other Income | 3 | 1 | 0 | −1 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 2 | 2 |
| Interest | 4 | 1 | 3 | 5 | 6 | 6 | 6 | 5 | 3 | 5 | 6 | 7 | 7 |
| Depreciation | 2 | 4 | 4 | 4 | 4 | 5 | 5 | 6 | 7 | 7 | 7 | 6 | 6 |
| PBT | −8 | −16 | −16 | −18 | −20 | −29 | −28 | −45 | −25 | −20 | −27 | −17 | −14 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
| Net Profit | −8 | −16 | −16 | −18 | −20 | −29 | −28 | −45 | −25 | −20 | −27 | −17 | −14 |
| EPS (₹) | −6.82 | −10.33 | −9.67 | −10.73 | −12.03 | −16.04 | −14.45 | −20.65 | −11.45 | −9.15 | −12.5 | −7.85 | −6.54 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 13 | 14 | 14 | 17 | 18 | 20 | 22 | 22 | 22 | 22 | 22 |
| Reserves | 9 | 0 | −12 | −32 | −31 | −43 | −62 | −97 | −121 | −141 | −168 | −184 |
| Borrowings | 61 | 31 | 48 | 56 | 53 | 66 | 111 | 143 | 183 | 194 | 212 | 225 |
| Other Liabilities | 29 | 73 | 73 | 87 | 103 | 93 | 91 | 122 | 91 | 104 | 103 | 101 |
| Total Liabilities | 108 | 116 | 122 | 126 | 142 | 134 | 159 | 190 | 175 | 178 | 169 | 163 |
| Fixed Assets | 58 | 93 | 102 | 101 | 101 | 105 | 118 | 139 | 147 | 150 | 146 | 142 |
| CWIP | 0 | 11 | 4 | 4 | 3 | 4 | 12 | 8 | 4 | 2 | 3 | 2 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 50 | 13 | 16 | 21 | 38 | 24 | 29 | 43 | 24 | 26 | 20 | 20 |
| Total Assets | 108 | 116 | 122 | 126 | 142 | 134 | 159 | 190 | 175 | 178 | 169 | 163 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | −45 | −15 | −11 | −6 | 4 | −36 | −15 | −17 | −25 | 2 | −8 | −2 |
| Investing | −3 | −4 | −5 | −3 | −4 | −10 | −23 | −23 | −13 | −8 | −5 | −4 |
| Financing | 54 | 13 | 16 | 9 | 17 | 29 | 38 | 40 | 37 | 6 | 13 | 6 |
| Net Cash Flow | 6 | −6 | 0 | 0 | 17 | −17 | 1 | −1 | 0 | 0 | 0 | 0 |
| Free Cash Flow | −48 | −23 | −17 | −9 | −1 | −45 | −40 | −41 | −36 | −5 | −11 | −5 |
| CFO/OP | 924 | 123 | 140 | 83 | −40 | 191 | 83 | 51 | 157 | −27 | 52 | 35 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | — | 10 | 180 | 3 | 22 | 2 | 2 | 5 | 4 | 14 | 0 | 0 |
| Inventory Days | — | 14,704 | 2,162 | 337 | 142 | 345 | 234 | 230 | 170 | 543 | 396 | — |
| Days Payable | — | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | 4,360 | 510 | 339 | 521 | 292 | 340 | 217 | 1,051 | 1,192 | — |
| Cash Conversion Cycle | — | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | −2,018 | −170 | −175 | −174 | −57 | −106 | −44 | −494 | −795 | 0 |
| Working Capital Days | — | −6,532 | −2,132 | −275 | −315 | −267 | −187 | −261 | −232 | −322 | −787 | −1,593 |
| ROCE % | — | −26% | −26% | −26% | −36% | −57% | −40% | −57% | −29% | −19% | −30% | −15% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Krebs Biochemicals & Industries insights
60 extracted metrics across FY11–FY27.
Documents
- 29 Oct 2026
- 6 Aug 2026
- 21 May 2026
- 9 Feb 2026
- 4 Nov 2025
- Intimation 16 Oct 2026
- General announcements 5 Oct 2026
Frequently Asked Questions about Krebs Biochemicals & Industries
What does Krebs Biochemicals & Industries Ltd do?
Incorporated in 1991, Krebs Biochemicals & Industries Ltd is presently engaged in manufacturing of active pharmaceutical ingredients.
Where is Krebs Biochemicals & Industries Ltd (KREBSBIO) listed?
Krebs Biochemicals & Industries Ltd trades as KREBSBIO on the NSE and under code 524518 on the BSE.
Which sector does Krebs Biochemicals & Industries Ltd belong to?
Krebs Biochemicals & Industries Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the 52-week high and low of Krebs Biochemicals & Industries Ltd?
Over the last 52 weeks Krebs Biochemicals & Industries Ltd has traded between ₹38.33 and ₹76.85 as of 4 Nov 2026.
Company Information
Incorporated in 1991, Krebs Biochemicals & Industries Ltd is presently engaged in manufacturing of active pharmaceutical ingredients.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/KREBSBIO.md for Krebs Biochemicals & Industries Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.